Destination: Cure

Revving Up Investigational agent ABX 464 seeks to reduce HIV reservoirs by Jeannie Wraight ABX 464 is making its way through clinical trials, showing strong potential as...

Gaining Momentum HIV vaccine candidates seek to make good on their early promise by Jeannie Wraight and David Miller Over the past several years, momentum for the...

Everyone Counts Differences in intravenous drug users may affect their response to an HIV vaccine by Jeannie Wraight Prevention strategies such as Treatment as Prevention, PrEP, syringe...

Step by Step At CROI 2017, HIV remission studies focus on early antiretroviral therapy initiation by Jeannie Wraight This year marked the 24th annual Conference on Retroviruses...

Buyer Beware The new administration may threaten HIV care and cure research by Jeannie Wraight Our way of life in the U.S. has already drastically changed as...

Hide & Seek Paul Volberding, MD, helps create synergy at the amfAR Institute for Cure Research by Jeannie Wraight The amfAR Institute for HIV Cure Research was...

Hiding Place One focus of the amfAR 2016 CURE Summit targeted HIV reservoirs by Jeannie Wraight This year, amfAR marked World AIDS Day with the 2016 HIV...

Beyond One Bug, One Drug Broad spectrum antivirals shift the drug model paradigm, part II by Jeannie Wraight In the October issue of A&U, Destination: Cure explored...

Spectrum Analysis Broad spectrum antivirals shift the drug model paradigm by Jeannie Wraight The recent spread of emerging pandemic viruses such as Zika and Ebola has increased...

Step Forward Vaccine candidates like HTVN 702 are needed to build momentum by Jeannie Wraight If current HIV diagnoses rates persist, about 1 in 2 black men...